T1	Participants 88 128	patients with non-small cell lung cancer
T2	Participants 2 21	randomized phase II
T3	Participants 743 895	Patients were eligible if they had stage I-IIIB NSCLC, unsuitable for curative therapy, or stage IV with a PET-detected extracranial solitary metastasis
T4	Participants 1290 1327	Eighty-four patients were randomized.
